Released Mar 20, 2025, after the close
10-K filed Mar 20, 2025, 79 days after period end · 0000950170-25-042673
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$7.36M$7.36M derived+2.7% vs Q4 2023+7.5% vs Q3 2024
Net Income-$10.34M-$10.34M derivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$11,532,000N/M
Operating Cash Flowderived-$407,000N/M
Free Cash Flowderived-$407,000N/M
Margins · derived
Operating margin-156.7%+18.5 pt vs Q4 2023
Net margin-140.5%+12.6 pt vs Q4 2023
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $7.36M | $7.16M | — | — |
| Net Income | -$10.34M | -$10.96M | -$22.40M | -$60.26M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR